Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime Buys 7,000 Shares

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime bought 7,000 shares of the firm’s stock in a transaction on Monday, March 24th. The stock was purchased at an average cost of $8.21 per share, with a total value of $57,470.00. Following the completion of the acquisition, the director now directly owns 23,615 shares of the company’s stock, valued at approximately $193,879.15. The trade was a 42.13 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Immunome Price Performance

IMNM stock opened at $6.95 on Wednesday. Immunome, Inc. has a 1 year low of $6.94 and a 1 year high of $26.70. The company has a market cap of $604.31 million, a P/E ratio of -0.86 and a beta of 1.93. The stock’s fifty day moving average price is $9.67 and its 200-day moving average price is $11.44.

Immunome (NASDAQ:IMNM) last announced its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The firm had revenue of $2.74 million during the quarter, compared to analysts’ expectations of $3.07 million. As a group, analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

IMNM has been the subject of several analyst reports. Guggenheim reduced their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. Lifesci Capital assumed coverage on Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target for the company. Stephens reaffirmed an “overweight” rating and set a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Finally, Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a report on Thursday, March 20th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $25.50.

Institutional Trading of Immunome

Several large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets bought a new position in Immunome in the fourth quarter worth approximately $70,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Immunome in the 4th quarter worth $75,000. AlphaQuest LLC raised its holdings in Immunome by 786,700.0% in the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after purchasing an additional 7,867 shares during the period. Tower Research Capital LLC TRC lifted its position in Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock valued at $91,000 after purchasing an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in Immunome during the fourth quarter valued at about $95,000. 44.58% of the stock is currently owned by institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.